The current research was conducted to evaluate the influence of newly developed probiotic (Microzist) and commercial probiotic (Primalac) on growth performance, carcass characteristics, and immunity of broiler chickens. A total of 225 one-day-old broiler chicks Ross-308 was randomly assigned into 5 groups – control group, group with 0.2, 0.25, and 0.3 g/kg of Microzist, and group constituting Primalac (starter: 0.9 g/kg, grower: 0.454 g/kg, and finisher: 0.225 g/kg). At 42nd day of age, there were no statistically significant differences among treatments on daily weight gain and feed conversion ratio (P > .05), but treatment’s effect on the feed intake was found to be significant (P < .05). Diet supplementation with various concentrations of Microzist showed growth performance of broiler chickens more or less similar to the Primalac additives. There were statistically significant differences (P < .05) among treatments on the carcass characteristics. Microzist (0.2 g/kg) reduced the abdominal fat content in broiler chickens in a comparison with control as well as Primalac (P < .05). Furthermore, Microzist showed no influence on the immunological organ weights. The present investigation indicates that Microzist may be a potential alternative to antibiotic growth promoters as well as widely used Primalac in broiler industries.
No takes yet. Share an insight, caveat, or question.
Parsa et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: